Addex Therapeutics Ltd - Company Profile
Powered by 
All the data and insights you need on Addex Therapeutics Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Addex Therapeutics Ltd Strategy Report
- Understand Addex Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Addex Therapeutics Ltd (Addex) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson's disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction, and mild neurocognitive and neurodegenerative disorders. The company has collaboration with Janssen Pharmaceuticals, Indivior PLC, government organizations and other academic researchers. Addex is headquartered in Geneva, Switzerland.
Headquarters
Switzerland
Address
Chemin Des Mines, 9, Plan-Les-Ouates, 1202
Website
www.addextherapeutics.com
Telephone
41 22 8841555
No of Employees
22
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADXN (SWF)
Revenue (2022)
$1.5M
-54.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-36.9%
(2022 vs 2021)
Market Cap*
$6.9M
Net Profit Margin (2022)
XYZ
-198.7%
(2022 vs 2021)
* As of and is in US$
Addex Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline - |
| Dipraglurant-IR: for PD- Levodopa Induced Dyskinesia |
| ADX71149: Epilepsy |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Contracts/Agreements | In February, the company entered into a research agreement with Enamine Ltd to efficiently support Addex’ small molecule CNS drug discovery programs. |
| 2019 | Research Grant | In July, the company received grant of EUR4.85 million from the Eurostars to develop novel allosteric modulator for the treatment of post-traumatic stress disorder. |
| 2018 | Research Grant | In September, the company received EUR1.2 million from The Wellcome Trust to carry out research as a part of Human Drug and Brain Research (THuNDR2) initiative. |
Competitor Comparison
| Key Parameters | Addex Therapeutics Ltd | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Novartis AG | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | United States of America | Switzerland | United Kingdom |
| City | Plan-Les-Ouates | Basel | Kenilworth | Basel | Cambridge |
| State/Province | - | - | New Jersey | - | England |
| No. of Employees | 22 | 103,613 | 69,000 | 103,000 | 83,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vincent Lawton | Chairman | Executive Board | - | 74 |
| Tim Dyer | Chief Executive Officer; Director | Executive Board | - | 55 |
| Roger G. Mills, M.D. | Chief Medical Officer; Director | Executive Board | - | 66 |
| Jean-Philippe Rocher | Head - Discovery- Chemistry | Senior Management | - | 64 |
| Robert Lutjens | Head - Discovery- Biology | Senior Management | - | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward